Redeon

Redeon is a biotechnology company focused on developing next-generation small molecule inhibitors targeting the DNA Damage Response (DDR) pathway to treat various forms of cancer. The company's primary focus is on creating highly selective inhibitors for key DDR enzymes, including DNA-PK, ATM, and ATR, which play critical roles in maintaining genomic stability in tumor cells. By inhibiting these targets, Redeon aims to sensitize cancer cells to DNA-damaging agents like radiotherapy and chemotherapy, or to induce synthetic lethality in tumors with specific genetic vulnerabilities. The company is currently in the pre-clinical stage, advancing its lead programs toward IND-enabling studies.